Easywell Biomedicals, Inc. (TPEX:1799)

Taiwan · Delayed Price · Currency is TWD

30.05

+0.10 (0.33%)

Sep 8, 2026, 11:25 AM CST

Market Cap	3.73B -34.3%
Revenue (ttm)	799.94M +32.2%
Net Income	-15.64M
EPS	-0.13
Shares Out	124.69M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	154,467
Open	30.20
Previous Close	29.95
Day's Range	30.00 - 30.50
52-Week Range	27.65 - 55.20
Beta	-0.14
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2026

About Easywell Biomedicals

Easywell Biomedicals, Inc., together with its subsidiaries, develops, manufactures, and sells generic pharmaceutical ingredients and products in America, China, and Taiwan. The company develops TLX-001, an anti-cough medicine; TLX-005, an anti-urinary incontinence medicine; TLX-006 for the treatment of breast cancer in PMS women; TLX-007 and TLX-004, which are anti-depressants; TLX-008 for the prevention of pneumocystis pneumonia; TLX-012 for the treatment of epilepsy; TLX-017 for the treatment of chronic angina; and TLX-011 for the treatment o... [Read more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

Founded 1998

Country Taiwan

Stock Exchange Taipei Exchange

Ticker Symbol 1799

Full Company Profile

Financial Performance

In 2025, Easywell Biomedicals's revenue was 597.41 million, an increase of 10.54% compared to the previous year's 540.44 million. Losses were -73.14 million, -24.96% less than in 2024.

Financial Statements